Transthyretin (ATTR) amyloidosis is a deadly disease caused by protein aggregation and is increasingly recognized as an important cause of heart failure ([1–3][1]). In the past year and a half, 3 novel therapeutic drugs (patisiran, inotersen, and tafamidis) have emerged as the first U.S. Food and

中文翻译：

---

甲状腺素运载蛋白心脏淀粉样变性的骨闪烁扫描成像：仍有很多东西需要学习


甲状腺素运载蛋白 (ATTR) 淀粉样变性是一种由蛋白质聚集引起的致命疾病，并且越来越多地被认为是心力衰竭的重要原因 ([1–3][1])。在过去一年半的时间里，3种新型治疗药物（patisiran、inotersen和tafamidis）成为美国食品和药物管理局首批批准的药物。